Group 1 - Hansi Aitai Biopharmaceutical Technology (Wuhan) Co., Ltd. successfully listed on the Hong Kong Stock Exchange on December 23, becoming the 71st listed company in the Optics Valley region [1] - The IPO involved a global offering of 18.321 million shares at an issue price of HKD 32 per share, raising a total of HKD 586 million, with a market capitalization of nearly HKD 4.4 billion [1] - Hansi Aitai focuses on developing innovative drugs for precise treatment of cancer and autoimmune diseases, with a pipeline of 10 candidate drugs, including 3 in clinical stages and 7 in preclinical stages [1] Group 2 - The founder of Hansi Aitai, Zhang Faming, is a professor and doctoral supervisor at Wuhan University School of Pharmacy, and has been an entrepreneur in the innovative drug field for 16 years [2] - The total number of listed companies in the Optics Valley region has reached 71, accounting for over 60% of the city's total and approximately one-third of the province's total [2] - In the life and health sector, there are currently 9 listed companies in the Optics Valley, with 6 companies undergoing listing review and 19 companies starting IPO counseling [2]
翰思艾泰募资5.86亿港股上市 武汉光谷上市公司增至71家